Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Growth hormone (GH) activity is associated with increased serum oestradiol and reduced Anti-Müllerian Hormone in healthy male volunteers treated with GH and a GH antagonist

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Long-term testosterone undecanoate treatment in the elderly testosterone deficient male - an observational cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Semen quality and waiting time to pregnancy explored using association mining

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Long-term testosterone undecanoate treatment in the elderly testosterone deficient male - an observational cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Bilateral oophorectomy and rate of colorectal cancer: A prospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Vitamin D supplementation improves fasting insulin levels and HDL cholesterol in infertile men

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Treatment options for hypercalcemia after cosmetic oil injections: Lessons from human tissue cultures and a pilot intervention study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Endocrine Disrupting Chemicals and Risk of Testicular Cancer: A Systematic Review and Meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations
Growth hormone (GH) and insulin-like growth factor I (IGF-I) receptors are present on pituitary gonadotrophs and on testicular Leydig and Sertoli cells. Thus, the GH/IGF-I system may modulate the pituitary-gonadal axis in males. This is a randomized cross-over study. Eight healthy male volunteers (mean age 35, range 29-46 years) were treated with GH for 3 weeks (1st week 0.01, 2nd week 0.02, 3rd week 0.03 mg/day/kg) or a GH receptor antagonist (Pegvisomant) (1st week 10, last 2 weeks 15 mg/day), separated by 8 weeks of washout. Before and after the two treatment periods, concentrations of luteinizing hormone (LH), follicle-stimulating hormone, testosterone, oestradiol, sex hormone-binding globulin, inhibin B and Anti-Müllerian Hormone (AMH) were measured. During GH treatment, IGF-I increased [(median (IQR)] 166 (162-235) vs. 702 (572-875) μg/L, p <0.001) together with oestradiol [(mean ± SD) 78 ± 23 vs. 111 ± 30 pm, p = 0.019], and the oestradiol/testosterone ratio (p = 0.003). By contrast, AMH (42 ± 14 vs. 32 ± 7 pm, p = 0.018), Inhibin B (211 (146-226) vs. 176 (129-204) ng/L, p = 0.059) and LH (3.8 ± 1.5 vs. 3.2 ± 1.2 U/L, p = 0.096) decreased. During pegvisomant treatment IGF-I (204 (160-290) vs. 106 (97-157) μg/L, p = 0.001) and oestradiol (86 ± 28 vs. 79 ± 25 pm, p = 0.060) decreased. No significant changes or trends in the other reproductive hormones occurred during the two treatment regimens. GH/IGF-I activity was positively associated with serum oestradiol, suggesting that GH/IGF-I stimulates aromatase activity in vivo. As a novel observation, we found that high GH activity was associated with reduced levels of the Sertoli cell marker AMH. Further studies are needed to evaluate possible effects of GH on Sertoli cell function and/or spermatogenesis.
Original languageEnglish
JournalAndrology
Volume1
Issue number4
Pages (from-to)595-601
Number of pages7
ISSN2047-2927
DOIs
Publication statusPublished - Jul 2013

ID: 39014927